CG Oncology, Inc.: chief commercial officer Isabel Kalofonos received 92,000 shares

What happened Isabel Kalofonos, chief commercial officer, received an award of 92,000 shares on Oct 15, 2026. The filing reports an acquisition price of $0.00 and a reported value of $0. Transaction type code A (award/derivative).

Key details

• Transaction date and price: Oct 15, 2026; $0.00 per share; transaction code A (award/derivative).
• Shares acquired: 92,000.
• Shares owned after the transaction: not reported in the provided filing.
• Footnote F1: the award vests over a four-year period starting on Oct 13, 2026; 25% vests after 12 months and the remainder vests in 36 equal monthly installments, subject to continuous service through each vesting date.
• Filing date and timeliness: filed Oct 19, 2026; filing appears to be timely.

Why it may matter This filing reports an award of derivative securities subject to vesting rather than a market purchase or sale. The filing does not show why the insider traded or why the company acted.